ClinPharm Consulting Announces Reorganization of Executive Leadership

Published: Sep 01, 2011

(Research Triangle Park, N.C.) ClinPharm Consulting, a specialized consulting firm offering a unique paradigm for empowering drug development pipelines, announced two major staffing changes to further integrate its scientifically sound PK-PD services with new approaches to reduce risk to drug development programs and maximize return on R&D investment.

Chief Scientific Officer M. Alexander Shaw, Ph.D., has been promoted to Chief Operating Officer, while Bill Wargin, Ph.D., has taken over as the firm’s new Chief Scientific Officer.

“Bill has been working with us since 2008 focusing on pharmacokinetic strategic planning for our clients’ pre-clinical and clinical programs, and his 25 years of experience in the pharmaceutical industry brings a huge knowledgebase of drug development experience to the table,” ClinPharm Consulting President & CEO Geoffrey Banks, Ph.D., said.

According to Dr. Banks, Dr. Wargin’s transition into the CSO role has been seamless as Dr. Shaw transitions to a wider role within the company to rollout and formalize new services designed to meet the needs of the firm’s diverse customers and projects.

“Our client base of pharmaceutical and biotechnology companies continues to expand,” Dr. Banks explained, adding, “ClinPharm Consulting’s high level of exposure to numerous clinical pharmacology programs is precipitating our introduction of common sense approaches and new paradigms to early phase drug development.”

The new services are being driven by valuable insights into preventable problems associated with clinical pharmacology studies that ClinPharm Consulting has developed through its diverse client work, and include new mechanisms for saving time and money while identifying the most salient data to use for downstream decision-making.

As CSO, Dr. Wargin will drive scientific and PK strategy for clients’ drug development programs, including the representation of clients during interactions with the FDA and support for ClinPharm Consulting’s new services that will be unveiled in the near term.

“Dr. Wargin’s experience will bring value-added insight across all of our clients and projects,” Dr. Banks said.

ClinPharm Consulting will be announcing details on its new services in September 2011, in advance of the firm’s participation in this fall’s American Association of Pharmaceutical Scientists Annual Meeting. For more information email or visit


ClinPharm Consulting is a specialized consulting firm offering a unique paradigm for empowering drug development pipelines. Our business model focuses on matching scientific and pharmacokinetic/pharmacodynamic expertise with superior writing capabilities to maximize the impact of individual studies on an overall clinical pharmacology program. We specialize in helping small biopharmaceutical companies with minimal R&D infrastructure find scalable solutions for emerging early phase drug development challenges, providing an unmatched combination of technical expertise and robust understanding of clinical pharmacology from a scientific, regulatory and clinical conduct perspective.

The breadth of our experience allows ClinPharm Consulting to be a complete resource for clients to set up their drug development programs for success. ClinPharm Consulting typically engages clients as early as the IND planning stage to develop robust clinical pharmacology strategies and then works as a horizontally integrated, in-house resource to assist with the execution and analysis of those strategies. Our efforts not only include the design, conduct, and analysis of clinical pharmacology studies but also helping clients transition from nonclinical research into early phase clinical trials as well as transitioning from healthy volunteers into patients with the target disease. For more information, visit

Back to news